New antibody drug firsekibart tested for scleroderma skin thickening
NCT ID NCT07502105
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial will test a new drug called firsekibart in 30 people with systemic sclerosis (scleroderma), a disease that causes skin thickening and organ damage. Firsekibart is an antibody that blocks a protein involved in inflammation. The study will measure changes in skin thickness over time and compare results to past patient data to see if the drug is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
firsekibart (a lab-made antibody that blocks IL-1β, a protein involved in inflammation)
What this could lead to
If it works, this could point toward a new treatment option for systemic sclerosis, potentially reducing skin thickening and improving quality of life.
What could go wrong
This is a very early, small, exploratory trial with only 30 participants and no placebo group. Results may not be generalizable, and the drug's safety and effectiveness are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Tong ji Medical Colledge
Wuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••